Utility of Serum Neurofilament Light Protein as a Biomarker in Traumatic Brain Injury DOI Open Access

Shalini Pasupuleti Satish Kumar

International Journal of Science and Research (IJSR), Год журнала: 2023, Номер 12(2), С. 468 - 473

Опубликована: Фев. 5, 2023

Objective: Traumatic Brain Injury (TBI) is the most predominant cause of morbidity globally. The load TBI in all age groups leads to a raise cost treatment. addition blood biomarkers can provide more reliable information about neuronal injury and aid clinical evaluation without sacrificing sensitivity. They may also serve as -effective tools with good specificity TBI. Methodology: 34 severe patients between 2019 2020, admitted Nizam's Institute Medical Sciences, Hyderabad, India were enrolled.30 orthotrauma (OT) 30 Healthy controls included study. All participants assessed for serum levels Neurofilament Light protein (NFL) S100B. Results: Serum NFL S100B concentrations on day 0 ranged from 150.8 414.6 pg/ml 705.26 3747.37 pg/L. was markedly higher than OT patients. values at d0 after NF -L (p=0.012) (p=0.202) over hospital stay significantly non survivors vs. survivors. Conclusion: would help better prognostication Measurement be useful assess axonal degeneration by knowing severity especially long term impairment, Whereas, S100b diagnose disease.

Язык: Английский

Benchmarking of a multi-biomarker low-volume panel for Alzheimer’s Disease and related dementia research DOI
Laura Ibáñez, Menghan Liu, Aleksandra Beric

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Июнь 14, 2024

Alzheimer's Disease (AD) biomarker measurement is key to aid in the diagnosis and prognosis of disease. In research setting, participant recruitment retention optimization sample use, one main challenges that observational studies face. Thus, obtaining accurate established measurements for stratification maximizing use precious samples key. Accurate technologies are currently available biomarkers, mainly immunoassays immunoprecipitation liquid chromatography-mass spectrometry (IP-MS), some them already being used clinical settings. Although immunoassays- IP-MS based platforms provide multiplexing several different coding proteins there not a current platform can measure all stablished emerging biomarkers run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA

Язык: Английский

Процитировано

7
Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer's disease and related dementia research DOI Creative Commons
Laura Ibáñez, Menghan Liu, Aleksandra Beric

и другие.

Alzheimer s & Dementia, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 22, 2024

Abstract INTRODUCTION In the research setting, obtaining accurate established biomarker measurements and maximizing use of precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all emerging biomarkers in one run. The NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) a technology that requires 15 µL sample to more than 100 analytes. METHODS We compared AD‐relevant included NULISA against validated assays cerebrospinal fluid (CSF) plasma. RESULTS CSF measures amyloid beta 42/40, phosphorylated tau (p‐tau)217 highly correlated when measured by immunoassay, mass spectrometry, or NULISA. plasma, p‐tau217 performance similar reported with other predicting amyloidosis. Other show wide range correlation values depending on platform. DISCUSSION multiplexed produces reliable results useful settings, advantage measuring additional using minimal volume. Highlights tested novel dementia setting. Cerebrospinal

Язык: Английский

Процитировано

6
Genotype and clinical characteristics of patients with Wolfram syndrome and WFS1-related disorders DOI Creative Commons
Evan M. Lee, Megha Verma, Nila Palaniappan

и другие.

Frontiers in Genetics, Год журнала: 2023, Номер 14

Опубликована: Июнь 21, 2023

Objective: Wolfram syndrome (WFS) is an autosomal recessive disorder associated with juvenile-onset diabetes mellitus, optic atrophy, insipidus, and sensorineural hearing loss. We sought to elucidate the relationship between genotypic phenotypic presentations of which would assist clinicians in classifying severity prognosis more accurately. Approach: Patient data from Washington University International Registry Clinical Study for Syndrome patient case reports were analyzed select patients two mutations WFS1 gene. Mutations classified as being either nonsense/frameshift variants or missense/in-frame insertion/deletion variants. Missense/in-frame further transmembrane non-transmembrane based on whether they affected amino acid residues predicted be domains WFS1. Statistical analysis was performed using Wilcoxon rank-sum tests multiple test adjustment applied via Bonferonni correction. Results: A greater number genotype correlated earlier onset a severe presentation syndrome. Secondly, non-sense frameshift had than missense variants, evidenced by mellitus atrophy emerging significantly compared zero one In addition, in-frame demonstrated statistically significant dose-effect age among Summary/Conclusion: The results contribute our current understanding genotype-phenotype syndrome, suggesting that alterations coding sequences result changes Wolfram. impact these findings significant, will aid predicting accurate prognoses pave way personalized treatments

Язык: Английский

Процитировано

13
Clinical Trials for Wolfram Syndrome Neurodegeneration: Novel Design, Endpoints, and Analysis Models DOI Creative Commons

Guoqiao Wang,

Zhaolong Li,

Ling Chen

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Сен. 11, 2024

Wolfram syndrome, an ultra-rare condition, currently lacks effective treatment options. The rarity of this disease presents significant challenges in conducting clinical trials, particularly achieving sufficient statistical power (e.g., 80%). objective study is to propose a novel trial design based on real-world data reduce the sample size required for trials syndrome.

Язык: Английский

Процитировано

1
Genotype and Clinical Characteristics of Patients with Wolfram Syndrome and WFS1-related Disorders DOI Creative Commons
Evan M. Lee, Megha Verma, Nila Palaniappan

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Фев. 16, 2023

Wolfram syndrome (WFS) is an autosomal recessive disorder associated with juvenile-onset diabetes mellitus, optic atrophy, insipidus, and sensorineural hearing loss. We sought to elucidate the relationship between genotypic phenotypic presentations of which would assist clinicians in classifying severity prognosis more accurately.

Язык: Английский

Процитировано

2
Utility of Serum Neurofilament Light Protein as a Biomarker in Traumatic Brain Injury DOI Open Access

Shalini Pasupuleti Satish Kumar

International Journal of Science and Research (IJSR), Год журнала: 2023, Номер 12(2), С. 468 - 473

Опубликована: Фев. 5, 2023

Objective: Traumatic Brain Injury (TBI) is the most predominant cause of morbidity globally. The load TBI in all age groups leads to a raise cost treatment. addition blood biomarkers can provide more reliable information about neuronal injury and aid clinical evaluation without sacrificing sensitivity. They may also serve as -effective tools with good specificity TBI. Methodology: 34 severe patients between 2019 2020, admitted Nizam's Institute Medical Sciences, Hyderabad, India were enrolled.30 orthotrauma (OT) 30 Healthy controls included study. All participants assessed for serum levels Neurofilament Light protein (NFL) S100B. Results: Serum NFL S100B concentrations on day 0 ranged from 150.8 414.6 pg/ml 705.26 3747.37 pg/L. was markedly higher than OT patients. values at d0 after NF -L (p=0.012) (p=0.202) over hospital stay significantly non survivors vs. survivors. Conclusion: would help better prognostication Measurement be useful assess axonal degeneration by knowing severity especially long term impairment, Whereas, S100b diagnose disease.

Язык: Английский

Процитировано

0